Harmony Biosciences

Harmony Biosciences HRMY Stock

$33.76   -0.118346%
Add to favorites
Market Cap
$1.98B
LOW - HIGH [24H]
$33.01 - $34.32
VOLUME [24H]
$844.90K
P/E Ratio
11.17
Earnings per share
$3.02
ISIN
US4131971040
Price   Prediction

Harmony Biosciences Price Chart

Sorry, that's all we've gotfor now...

Harmony Biosciences (HRMY) stock price today is 33.76 USD on Tech Market Middle (-0.12% on the day). Updated .

Harmony Biosciences HRMY Financial and Trading Overview

Harmony Biosciences stock price 33.76 USD
Previous Close 33.8 USD
Open 33.8 USD
Bid 27.98 USD x 200
Ask 49.31 USD x 200
Day's Range 33.01 - 34.32 USD
52 Week Range 25.9 - 43.49 USD
Volume 844.9K USD
Avg. Volume 1.01M USD
Market Cap 1.98B USD
Beta (5Y Monthly) 0.976
PE Ratio (TTM) 11.178807
EPS (TTM) 3.02 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 48.08 USD

HRMY Valuation Measures

Enterprise Value 1.37B USD
Trailing P/E 11.178807
Forward P/E 5.5679245
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 2.0038157
Price/Book (mrq) 1.8488498
Enterprise Value/Revenue 1.381
Enterprise Value/EBITDA 5.584

Trading Information

Harmony Biosciences Stock Price History

Beta (5Y Monthly) 0.976
52-Week Change -0.67%
S&P500 52-Week Change 13.32%
52 Week High 43.49 USD
52 Week Low 25.9 USD
50-Day Moving Average 38.65 USD
200-Day Moving Average 34.57 USD

HRMY Share Statistics

Avg. Volume (3 month) 1.01M USD
Avg. Daily Volume (10-Days) 1.2M USD
Shares Outstanding 58.72M
Float 52.58M
Short Ratio 6.47
% Held by Insiders 2.10%
% Held by Institutions 104.13%
Shares Short 6.66M
Short % of Float 15.12%
Short % of Shares Outstanding 11.35%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 18.05%
Operating Margin (ttm) 22.17%
Gross Margin 74.03%
EBITDA Margin 24.73%

Management Effectiveness

Return on Assets (ttm) 10.20%
Return on Equity (ttm) 18.72%

Income Statement

Revenue (ttm) 989.36M USD
Revenue Per Share (ttm) 17.07 USD
Quarterly Revenue Growth (yoy) 12.30%
Gross Profit (ttm) 732.42M USD
EBITDA 244.7M USD
Net Income Avi to Common (ttm) 178.6M USD
Diluted EPS (ttm) 3.02
Quarterly Earnings Growth (yoy) -5.20%

Balance Sheet

Total Cash (mrq) 771.14M USD
Total Cash Per Share (mrq) 13.13 USD
Total Debt (mrq) 154.91M USD
Total Debt/Equity (mrq) 14.45 USD
Current Ratio (mrq) 3.443
Book Value Per Share (mrq) 18.26

Cash Flow Statement

Operating Cash Flow (ttm) 323.04M USD
Levered Free Cash Flow (ttm) 191.78M USD

Profile of Harmony Biosciences

Country United States
State PA
City Plymouth Meeting
Address 630 West Germantown Pike
ZIP 19462
Phone 484 539 9800
Website https://www.harmonybiosciences.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 293

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Q&A For Harmony Biosciences Stock

What is a current HRMY stock price?

Harmony Biosciences HRMY stock price today per share is 33.76 USD.

How to purchase Harmony Biosciences stock?

You can buy HRMY shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Harmony Biosciences?

The stock symbol or ticker of Harmony Biosciences is HRMY.

Which industry does the Harmony Biosciences company belong to?

The Harmony Biosciences industry is Biotechnology.

How many shares does Harmony Biosciences have in circulation?

The max supply of Harmony Biosciences shares is 58.72M.

What is Harmony Biosciences Price to Earnings Ratio (PE Ratio)?

Harmony Biosciences PE Ratio is 11.17880700 now.

What was Harmony Biosciences earnings per share over the trailing 12 months (TTM)?

Harmony Biosciences EPS is 3.02 USD over the trailing 12 months.

Which sector does the Harmony Biosciences company belong to?

The Harmony Biosciences sector is Healthcare.

Harmony Biosciences HRMY included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 25136.27 USD —
-0.91
7.74B USD — 24872.41 USD — 25423.09 USD — — 7.74B USD —
us US Tech Health Care IXHC US 1368.29 USD —
-0.34
— — 1358.68 USD — 1373.65 USD — — — —
us US Tech US 700 Small Cap Index NQUS700SC US 3020.37 USD —
-0.22
— — 2991.33 USD — 3035.56 USD — — — —
us US Tech Global Market Composite NQGM US 1937.83 USD —
-1.05
— — 1915.46 USD — 1955.74 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech US Smart Pharmaceuticals NQSSPH US 2347.16 USD —
+0.24
— — 2326.8 USD — 2354.9 USD — — — —
us US Tech AlphaDEX Multi Cap Growt NQDXUSMLTCG US 3748.08 USD —
-0.7
— — 3701.51 USD — 3782.39 USD — — — —
us US Tech Biotechnology NBI US 7211.27 USD —
-0.5
— — 7149.19 USD — 7238.9 USD — — — —
$2.19T
Total marketcap
$81.89B
Total volume
BTC 59.42%   •   ETH 10.08%
Dominance
Select currency